Extended Conventional Therapy In Adult Xlh Patients by Connor, Jessica Ann
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses School of Public Health
January 2015
Extended Conventional Therapy In Adult Xlh
Patients
Jessica Ann Connor
Yale University, jessicaconnor091@gmail.com
Follow this and additional works at: http://elischolar.library.yale.edu/ysphtdl
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an authorized administrator of EliScholar – A Digital Platform for
Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Connor, Jessica Ann, "Extended Conventional Therapy In Adult Xlh Patients" (2015). Public Health Theses. 1048.
http://elischolar.library.yale.edu/ysphtdl/1048
 
Extended Conventional Therapy in Adult XLH Patients  
 
 
Jessica Connor1, Elizabeth Olear M.S.2, Karl Insogna M.D.3 Lee Katz M.D.4, Suher Baker 
D.M.D.5, Raghbir Kaur D.M.D.5, Christine Simpson M.S.3, John Sterpka3, Robert Dubrow M.D. 
Ph.D.1, Jane Zhang Ph.D.6, Thomas Carpenter M.D.2  
 
Yale University School of Medicine (Epidemiology and Public Health1 and Departments of 
Medicine2, Pediatrics3, and Diagnostic Imaging4); Yale-New Haven Hospital Dentistry Program5, 
The Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System6 
 
 
 
 
 
 
 
 
 
 
Abstract  
Context: Treatment of X-linked hypophosphatemia (XLH) with active vitamin D metabolites and 
phosphate can partially correct skeletal deformities. It is unclear if therapy influences the 
occurrence of two major long-term morbidities in XLH: enthesopathy and dental disease.  
Objective: To investigate the relationship between treatment and enthesopathy and dental disease 
in adult XLH patients.  
Design: Observational and cross-sectional.  
Setting: Academic medical center’s hospital research unit.  
Participants: 52 XLH patients aged >= 18 at time of study.  
Interventions: None  
Main outcome measures: Number of enthesopathy sites identified by radiographic skeletal 
survey and dental disease severity (>5 or <=5 dental abscesses), identified historically.  
Methods: Associations between proportion of adult life and total life with treatment and number 
of enthesopathy sites were assessed using multiple linear regression, while associations between 
these exposure variables and dental disease severity were assessed using multiple logistic 
regression. All models were adjusted for confounding factors.  
Results: Neither proportion of adult nor total life with treatment was a significant predictor of 
extent of enthesopathy. In contrast, both of these treatment variables were significant predictors 
of dental disease severity (multivariate-adjusted global p-value =0.0080 and =0.0010 
respectively). Participants treated 0% of adulthood were more likely to have severe dental disease 
than those treated 100% of adulthood (adjusted OR 25 [95% CI 1.2-520]). As proportion of total 
life with treatment increased, the odds of having severe dental disease decreased (multivariate-
adjusted p-value for trend=0.015).  
Conclusions: Treatment in adulthood may not promote or prevent enthesopathy; however it may 
be associated with lower risk of experiencing severe dental disease. 
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Introduction 
X-linked hypophosphatemia (XLH), the most common form of heritable rickets, is a 
dominant disorder of phosphate homeostasis whose prevalence is estimated at 1 in 20,000 (1). 
The pathophysiology of this disease is related to loss of function mutations in the phosphate-
regulating endopeptidase gene (PHEX) (2). PHEX is normally expressed in bone and teeth and its 
disruption results in increased circulating levels of fibroblast growth factor 23 (FGF23) (3). 
FGF23 acts in an endocrine manner at the kidney to both decrease renal tubular reabsorption of 
phosphate and renal 1-α-hydroxylase activity resulting in the combined findings of 
hypophosphatemia and inadequate levels of circulating 1,25(OH)2D observed in XLH (2).  
Hypophosphatemia, low 1,25(OH)2D, and perhaps independently, elevated FGF23 and 
disruption of PHEX contribute to the broad range of severity in the skeletal and dental 
morbidities in XLH(1). Common skeletal abnormalities observed in XLH include bowing of the 
legs, anteromedial rotation and torsion of the tibiae, and poor bone mineralization (osteomalacia) 
with resultant growth retardation and bone disease (4). However, later in life, patients often 
experience mineralization of tendons and ligaments (enthesopathy) (1). Dental morbidities 
include delayed dentition and dental abscesses with the latter continuing throughout adult life (1). 
The current standard of therapy for XLH is a regimen of active vitamin D metabolites, 
usually calcitriol, and phosphate beginning at time of diagnosis and continuing to growth 
completion (1). The administration of these therapies intermittently increases serum phosphate, 
providing necessary mineral to the growing skeleton and thereby partially correcting leg 
deformities (5). After growth completion, the rationale for therapy is directed toward 
symptomatic osteomalacia and prevention or correction of fractures or insufficiency fractures (1). 
It remains to be established whether therapy affects the other major adult sequelae of XLH, 
particularly enthesopathy and dental disease.  
Continuing conventional treatment into adulthood has been controversial both because its 
efficacy is not well studied, and because it is burdensome and potentially toxic (4). Long-term 
2 
therapy with calcitriol and phosphate may result in hyperparathyroidism, hypercalcemia, 
hypercalciura, nephrocalcinosis, and in extreme cases, chronic kidney disease (4). However, if 
monitored for safety, treatment has been shown to improve certain features of the disease, 
including pain and osteomalacia (6). Therefore, it is of great clinical importance to establish the 
effect of therapy on enthesopathy and dental disease during adult life. Using data from a 
relatively large cohort of XLH patients this study examined the association between conventional 
XLH therapy and two significant morbidities experienced in the adult phase of the disease: 
enthesopathy and dental abscess formation.  
Materials and Methods 
Subjects and Design 
The study sample included 52 XLH patients age 18 or older. Patients were offered 
participation during clinical visits to the Yale Bone Center or upon referral from other physicians. 
The study population consisted of 18 males and 34 females. Exclusion criteria included presence 
of other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic, 
gastrointestinal disorders, and malignancy), treatment with estrogen or bisphosphonates, and 
pregnancy.  
Data Collection 
Biochemical measures reflecting pathophysiology or therapeutic toxicity were obtained 
for each study participant. Serum PTH was measured as area under the curve from samples 
obtained at 4-hour intervals for 8 consecutive intervals using a mid-region assay (7). FGF23 was 
measured as a single value from a fasting morning sample using the Kainos intact ELISA kit 
(kindly provided by Kyowa Hakko Kirin Pharma, Inc.). Participant characteristics, including age 
at onset of treatment, years with treatment, frequency of pain medication use, previous 
osteotomies, and number of dental abscesses were obtained from both medical records and 
extensive questioning of history. Research nursing staff measured participant height using a 
stadiometer and weight using a calibrated scale. These measurements were used to calculate both 
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height z-scores and body mass index (BMI) with the latter calculated as kilogram body weight 
per height in meters squared. Participants were genotyped by Sanger sequencing to determine the 
nature of their PHEX mutations. We categorized frame-shift and splice-site mutations as “severe” 
and missense and point mutations as “non-severe”. Sites of enthesopathy were determined via 
skeletal survey examined by a radiologist. The specific anatomic sites surveyed included 
shoulders, elbows, hands, wrists, pelvis, knees, ankle, and thoracic-lumbar spine. 
Exposures of Interest 
The primary exposure of interest in this study was treatment with calcitriol (or high dose 
vitamin D) and phosphate. Because of the importance of age in the natural history of this disease, 
treatment exposure was assessed as a proportion of both total years of life and total years of adult 
life. All years of life age 18 and over were counted towards adult life. Proportion of adult life 
with treatment was calculated by dividing total years of treatment in adult life by total years of 
adult life. This exposure variable was categorized into three levels based on the distribution of the 
sample:  0.0 of adult life with treatment, greater than 0.0 but less than 1.0 of adult life with 
treatment, and 1.0 of adult life with treatment. Proportion of total life with treatment was 
calculated by dividing total years of treatment throughout life by total years of life. This exposure 
variable was categorized into four levels based on the quartile distribution of the sample: <0.436, 
0.436-<0.588, 0.588-0.881, 0.881<=1.0.  
Outcomes of Interest   
There were two primary outcomes of interest in this study: number of sites of 
enthesopathy identified on an a priori designed skeletal survey, and number of dental abscesses 
experienced per participant. Enthesopathy was assessed as a continuous variable. Dental disease 
severity was assessed as a dichotomous variable: a history of  >5 dental abscesses (“severe” 
dental disease) versus a history of ≤ 5 dental abscesses (“non-severe” dental disease).  
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Statistical Analysis  
The association between each of our two primary exposure variables, proportion of adult 
life and proportion of total life with treatment, and number of sites of enthesopathy was assessed 
using multiple linear regression. The association between each of our two primary exposure 
variables and dental disease severity was assessed using multiple logistic regression, modeling 
the odds of having “severe” versus “non-severe” dental disease. Because of the importance of age 
in the natural history of XLH, all models included age as a covariate. Age-adjusted models 
included only the primary exposure variable of interest and age. In addition, the following 
variables were assessed as potential confounders of the relationship between the respective 
exposure variables and enthesopathy: sex, body mass index, mutation severity, PTHauc, and 
FGF23. Covariates were retained in the model if their addition resulted in a 10% or greater 
change in the parameter estimate for the primary exposure variable. Both fully adjusted models 
for enthesopathy included age, sex, body mass index, mutation severity, and PTHauc. Both fully 
adjusted models for dental disease included age, sex, and mutation severity. For all models 
assessing proportion of life with treatment as the primary predictor, proportion of childhood with 
treatment was also included as a covariate. Proportion of childhood with treatment was assessed 
as a dichotomous variable: <0.80 of childhood versus >= 0.80 of childhood. P-values for trend 
and global p-values were obtained for the primary predictor variables. All analyses were 
performed using the statistical software package SAS 9.3.  
Descriptive Statistics  
Table 1 presents selected participant characteristics across three groups defined by 
proportion of adult life with treatment. The mean age of the study sample was 39 years. The total 
years of childhood treatment (before age 18) was relatively similar across all groups with an 
overall sample average of 13.9 years. For the entire sample (as well as for each treatment 
category) there were approximately 35% males and 65% females, consistent with the X-linked 
dominant mode of inheritance. The majority of participants had severe vs. not severe mutations 
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(65% vs. 25%). On average, 1.8 sites of enthesopathy were identified per patient. Average sites of 
enthesopathy across the three proportional treatment categories did not differ notably. A majority 
of our sample had severe dental disease versus non-severe dental disease (61.5% vs. 38.5%). 
There were notable differences in dental disease severity across the adult life treatment 
categories: 75% of those participants with no (0%) treatment during adult life had severe dental 
disease while only 47% of those treated throughout all (100%) of adult life had severe dental 
disease.   
Enthesopathy 
Table 2 presents both age-adjusted and multivariate-adjusted multiple linear regression 
models of the relationship between proportion of adult life with treatment, as well as other 
predictors, and number of sites of enthesopathy. We found that after adjusting for age, proportion 
of adult life with treatment was not a significant predictor of number of sites of enthesopathy 
(age-adjusted global p-value=0.96) and this finding remained after adjusting for confounders 
(multivariate-adjusted global p-value=0.90). We did, however, find that age, BMI, and sex were 
important predictors of the number of sites of enthesopathy. Age and body mass index were 
positively associated with number of sites of enthesopathy (p<0.001 for each covariate). Female 
sex was negatively associated with number of sites of enthesopathy (p=0.0080). We found that 
females on average had 0.42 less sites of enthesopathy compared to males. We found borderline 
significant positive association between PTHauc and number of sites of enthesopathy. In contrast, 
mutation severity and proportion of treatment in childhood did not predict extent of enthesopathy 
(p=0.42 and p=0.10 respectively). Table 3 presents age-adjusted and multivariate-adjusted 
multiple linear regression models of the relationship between proportion of total life, as well as 
other predictors, and number of sites of enthesopathy for the purposes of comparison. Proportion 
of total life with treatment was also not a significant predictor of this outcome (age-adjusted 
global p-value= 0.18; multivariate-adjusted global p-value=0.90). Results for other covariates 
were similar to those seen in the model for proportion of adult life with treatment: age, BMI, and 
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PTHauc were positively associated with number of sites of enthesopathy while female sex was 
negatively associated with this outcome. However, the PTHauc association did not achieve 
borderline significance in this model (p=0.10).  
Dental Disease  
Table 4 presents age-adjusted and multivariate-adjusted multiple logistic regression 
models of the relationship between proportion of adult life with treatment, as well as other 
predictors, and severity of dental disease. In both the age-adjusted and multivariate-adjusted 
analyses, proportion of adult life with treatment was negatively associated with the odds of 
having severe dental disease (global p-value=0.038 and 0.0080 respectively). After adjustment 
for confounders, we found a borderline significant trend between increasing proportion of adult 
life with treatment and decreasing odds of having severe dental disease (p-value for trend=0.066). 
Those who were not treated at all during adult life were more likely to experience severe dental 
disease than those who were treated for 100% of adulthood (adjusted OR 25 [95% CI 1.2-520]). 
We found that age was a significant predictor of dental disease severity: for a 1 year increase in 
age, the odds of having severe dental disease increased by 10% (OR: 1.1 [95% CI 1.0-1.2]). 
Furthermore, we found that sex was a borderline significant predictor of dental disease severity 
(p=0.061). Females had lower odds of experiencing severe dental disease compared to males (OR 
0.15 [95% CI 0.020-1.1]). Those treated for less than 80% of childhood had higher odds of 
experiencing severe dental disease compared to those treated for 80% or greater of childhood 
(OR: 7.2 [95% CI 0.71-73]). Mutation severity was positively associated with severity of dental 
disease: those with severe mutations had higher odds of experiencing severe dental disease 
compared to those who did not have severe mutations (OR 3.9 [95% CI 0.63-25)]. These 
relationships did not, however, achieve statistical significance. Table 5 presents age-adjusted and 
multivariate-adjusted multiple linear regression models of the relationship between proportion of 
total life, as well as other predictors, and severity of dental disease. Proportion of total life with 
treatment was negatively associated with severity of dental disease (age-adjusted global p-value 
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0.012; multivariate-adjusted global p-value 0.0010). As proportion of total life with treatment 
increased, the odds of having severe dental disease decreased (age-adjusted p-value for 
trend=0.046; multivariate-adjusted p-value for trend=0.015). Results for other covariates were 
similar to those seen in the model for proportion of adult life with treatment: age and mutation 
severity were positively associated with dental disease severity while female sex was negatively 
associated with this outcome.  
Discussion 
The results of this study suggest that the extension of treatment for XLH with calcitriol 
and phosphate into adulthood neither prevents nor promotes enthesopathy, but may prove 
beneficial for the prevention of dental abscesses. Most previous work on the efficacy of this 
therapeutic regimen has focused on the pediatric XLH population and as a result there is currently 
not an established consensus regarding treatment of the adult patient. Moreover, the limited 
studies in the adult XLH population have not assessed the effect of therapy on the specific 
outcomes that were the focus of our study. Sullivan et al. conducted a prospective study of the 
relationship between phosphate and calcitriol treatment and biochemical, clinical, and histological 
responses in 16 adult XLH patients (7). They found that 87% of participants reported significant 
improvement in musculoskeletal symptoms and osteoid thickness was significantly reduced as 
well (7). Costa et al. assessed 5 “adult” patients (defined as >15 years of age) and 6 children with 
XLH and found that skeletal improvements were most pronounced in, but not limited to, the pre-
pubescent patients (8). Although these studies examined certain skeletal outcomes, neither 
assessed enthesopathy as an outcome and the sample sizes were too small to assess possible 
associations with treatment duration and skeletal outcomes.  
Although enthesopathy is well described in XLH patients, previous studies have not 
examined treatment effects on this complication. More numerous reports of dental complications 
exist; however a beneficial effect of medical therapy on dental outcomes has yet to be established 
(4). Furthermore, it is established that the management of dental abscesses via pulpectomy and 
8 
root canal often fails (11). Moreover, one dental abscess tends to predict the occurrence of future 
abscesses (10). In light of this information, our findings suggest that conventional therapy 
extended into adulthood may be particularly beneficial for XLH patients that have particularly 
burdensome dental disease. If management via traditional dental methods fails and one abscess 
predicts the next, continuation of pharmaceutical therapy may be indicated for these particular 
patients.  
Our finding of higher odds of severe dental disease in males versus females is consistent 
with clinical observation: male patients have been shown to have more extensive dental disease 
than females (12). It is believed that the more severe dental phenotype in males can be at least 
partially explained by the hemizygous nature of the disease allele in males, and that a more 
striking gene dose effect is evidence for the teeth than the skeleton (12). This theory may also 
explain our finding of a negative association between female sex and number of sites of 
enthesopathy. The positive association between age and the two outcomes of interest may be 
explained by the natural history of XLH: enthesopathy is known to be a morbidity of aging and 
the more time that elapses, the more opportunity there is for dental abscess to occur. Although we 
did not find proportion of adult life or proportion of total life to be important predictors of 
enthesopathy, the finding that body mass index was positively associated with number of sites of 
enthesopathy may be of clinical importance in that the increased load to insertion sites evident 
with increasing BMI, may accelerate the disease process (13). Thus, greater body mass index, and 
resultant increased load on the insertion sites may be an important factor in accelerating the 
development of this complication. Our findings suggest that although pharmacological therapy 
may not be effective for preventing enthesopathy, weight-loss interventions may be helpful in the 
long-term.  
In sum, we have assessed clinically significant outcomes of adult XLH that have not 
previously been adequately explored. Although the cross-sectional nature of this study limits its 
interpretation, the identification and use of a database for cumulative treatment history in adult 
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patients with XLH is unique and informative. A randomized control trial directed toward adult 
morbidities in XLH patients would be important to confirm the safety and efficacy of continued 
treatment through adult years, however such a study is likely to require a lengthy follow up 
period to capture sufficient for these age-dependent outcomes to develop.  
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Table 1. Selected participant characteristics by proportion of adult Life with treatment a 
 
Characteristic 
 
 
                      N 
0% of Adult life 
with treatment b 
 
8  
0%<x<100% of 
Adult life with 
treatment b 
27 
100% of Adult 
life with 
treatment b 
17 
Full sample b 
 
 
52 
Age (yrs) 31.8 (11.3) 40.7 (11.9) 39.9 (18.4) 39.0 (14.4) 
 
Age at onset of 
treatment (yrs) 
 
4.7 (8.3) 
 
6.6 (11.5) 
 
4.0 (6.9) 
 
5.4 (9.7) 
 
Yrs of treatment 
>= age 18  
 
1.6 (4.3) 
 
6.4 (6.7)  
 
20.9 (17.8) 
 
10.5 (13.5) 
 
Yrs of treatment 
<18 
 
14.0 (6.3) 
 
13.5 (6.1) 
 
14.5 (4.6) 
 
13.9 (5.6) 
 
Sex 
Male 
Female  
 
 
3 (37.5) 
5 (62.5) 
 
 
9 (33.3) 
18 (66.7) 
 
 
6 (35.3) 
11 (64.7) 
 
 
18 (34.6) 
34 (65.4) 
 
BMI (kg/m2) 
 
34.1 (11.2) 
 
34.2 (10.4) 
 
31.4 (5.9) 
 
33.3 (9.2) 
 
Body fat % 
 
36.9 (11.1) 
 
34.3 (11.7) 
 
35.4 (12.4) 
 
35.1 (11.5) 
 
Height Z-score 
>= -1.0 
-1.1=<z<= -1.5 
-1.6 -2.0 
-2.1  
 
 
 
0 (0.0) 
1 (12.5) 
2 (25.0) 
5 (62.5) 
 
 
4 (14.8) 
2 (7.4) 
2 (7.4) 
19 (70.4) 
 
 
0 (0.0) 
3 (17.7) 
2 (11.8) 
12 (70.6) 
 
 
4 (7.7) 
6 (11.5) 
6 (11.5) 
36 (69.2) 
Use of pain meds 
Never 
Less frequently 
Weekly 
Daily 
> once/day 
 
1 (12.5) 
2 (25.0) 
3 (37.5) 
1 (12.5) 
1 (12.5) 
 
7 (25.9) 
4 (14.8) 
5 (18.5) 
7 (25.9) 
4 (14.8) 
 
5 (31.3) 
5 (31.3) 
2 (12.5) 
4 (25.0) 
0 (0.0) 
 
13 (25.5) 
11 (21.6) 
10 (19.6) 
12 (23.5) 
5 (9.8) 
 
Previous no. of 
osteotomies  
    none 
1  
2  
>2 
 
 
 
 
 
4 (50.0) 
0 (0.0) 
2 (25.0) 
2 (25.0) 
 
 
 
 
 
11 (40.7) 
0 (0.0) 
7 (25.9) 
9 (33.3) 
 
 
 
3 (17.7) 
2 (11.8) 
3 (17.7) 
9 (52.9) 
 
 
 
18 (34.6) 
2 (3.9) 
12 (23.1) 
20 (38.5) 
 
 
 
 
 
 
 
 
 
 
2 
Mutation statusc 
Not severe 
Severe  
 
 
1 (12.5) 
6 (75.0) 
 
9 (33.3) 
17 (63.0) 
 
3 (17.7) 
11 (64.7) 
 
13 (25.0) 
34 (65.4) 
No. of sites of 
enthesopathy  
1.63 (0.74) 
 
1.85 (0.86) 
 
1.82 (0.64) 
 
1.81 (0.77) 
 
No. of dental 
abscesses  
<=5 
>5 
 
2 (25.00) 
6 (75.00) 
 
 
9 (33.3) 
18 (66.7) 
 
9 (52.9) 
8 (47.1) 
 
 
20 (38.5) 
32 (61.5) 
 
PTHd 
 
1068.5 (889.9) 
 
985.6 (392.4) 
 
1260.7 (751.8) 
 
1088.3 (616.5) 
 
FGF23 
 
1976.5 (972.4) 
 
6156.9 
(140508.8) 
 
4604.2 (7260.8) 
 
5006.2 (11233.0) 
 
a Table values are mean ± SD for continuous variables and n (column %) for categorical 
variables. 
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due 
to rounding. 
c 5 missing values for mutation severity were included in a “missing category”  
dPTH, area under the curve measure for PTH samples taken every 4 hours over a 26-hr period 
 
 
 
 
 
 
	 	
Table 2. Age-adjusted and multivariate-adjusted multiple linear regression models of the 
relationship between proportion of adult life with treatment, other predictors, and sites of 
enthesopathy  
 
Characteristic  Age-adjusted Multivariate-Adjusted 
β(SE) P-value β (SE) P-value  
Proportion of adult 
life with treatment  
    
   0 0.071 (0.27) 0.80 -0.092 (0.23) 0.69 
   0<x<1 0.0040 (0.19) 0.99 -0.0000015 (0.17) 1.0 
   1 Reference - Reference  - 
Global p-value  0.96  0.90 
P-value for trend   0.68  0.50 
     
Age (years) 0.033 (0.010) <0.0010 0.023 (0.006) <0.0010 
     
Sex      
   Male - - Reference   
   Female  - - -0.42 (0.16) 0.0080 
     
Body mass index 
(kg/m2) 
- - 0.034 (0.0090) <0.0010 
     
Mutation severitya     
   Not Severe - - Reference   
   Severe  - - 0.14 (0.18) 0.42  
     
PTHb  - - 0.00028 (0.00014) 0.051 
     
Proportion of 
treatment in 
childhood  
    
   <0.80 - - 0.30 (0.18) 0.10  
   ≥0.80 - - Reference   
 
a  Mutation analyses from 5 subjects were either not preformed or not definitive and were 
included in a “missing” category  
bPTH, area under the curve measure for PTH samples taken every 4 hours over a 26-hr period 
 
 
	 	
Table 3. Age-adjusted and multivariate-adjusted multiple linear regression models of the 
relationship between proportion of total life with treatment, other predictors, and number 
sites of enthesopathy  
 
Characteristic  Age-adjusted Multivariate-Adjusted 
     β(SE) P-value     β (SE) P-value  
Proportion of total 
life with treatment 
  
    
   0<=x<0.436 0.012 (0.24) 0.96 0.094 (0.21) 0.66 
   0.436<=0.588 0.19 (0.24) 0.43 0.027 (0.23) 0.91 
   0.588<=x<0.881 -0.20 (0.24) 0.41 -0.050 (0.21) 0.81 
   0.881<=x<=1.0 Reference  - Reference  - 
Global p-value  0.18  0.90 
P-value for trend  
 
 0.72  0.54 
Age (years) 
 
0.031 (0.0060) <0.0010 0.027 0(0.0060) <0.0010 
Sex      
   Male - - Reference - 
   Female  
 
- - -0.42 (0.60) 0.012 
Body mass index  
(kg/m2) 
 
- - 0.030 (0.010) 0.0020 
Mutation severitya     
   Not Severe - - Reference  - 
   Severe  
 
  0.17 (0.18) 0.34 
PTHb  - - 0.00025 (0.00015) 0.10 
 
a5 missing values for mutation severity were included in a “missing category”  
bPTH, area under the curve measure for PTH samples taken every 4 hours over a 26-hr period 
 
	 	
 
Table 4. Age-adjusted and multivariate-adjusted multiple logistic regression models of the 
relationship between proportion of adult life with treatment, other predictors, and severity 
of dental disease  
 
Characteristic  Age-adjusted Multivariate-Adjusted 
OR (95% CI) P-value  OR (95% CI) P-value  
Proportion of adult 
life with treatment  
    
   0 7.8 (0.85-71) 0.069 25 (1.2-520) 0.038 
   0<x<1 2.3 (0.51-11) 0.27 7.1 (0.88-58) 0.067 
   1 1.0 - 1.0 - 
Global p-value  0.038  0.0080 
P-value for trend   0.20  0.066 
 
Age (years) 
 
1.1 (1.0-1.2) 
 
0.0030 
 
1.1 (1.0-1.2) 
 
0.019 
 
Sex  
    
   Male - - 1.0 - 
   Female  - - 0.15(0.020-1.1) 0.061 
 
Mutation severitya 
    
   Not Severe - - 1.0  
   Severe  - - 3.9 (0.63-25) 0.14 
 
Proportion of 
treatment in 
childhood  
    
   <0.80 - - 7.2 (0.71-73) 0.10 
   ≥0.80 - - 1.0 - 
 
a5 missing values for mutation severity were included in a “missing category”  
 
 
	 	
Table 5. Age-adjusted and multivariate-adjusted multiple linear regression models of the 
relationship between proportion of adult life with treatment, other predictors, and sites of 
enthesopathy  
 
 
Characteristic  
 
Age-adjusted 
 
Multivariate-Adjusted 
 OR (95% CI) P-value OR (95% CI) P-value  
Proportion of total 
life with treatment  
    
   0<0.436 8.8 (1.1-70) 0.040 31 (2.2-450) 0.012 
   0.436≤0.588 5.6 (0.84-38) 0.075 25 (1.8-340) 0.017 
   0.588≤0.881 2.0 (0.33-12) 0.45 4.8 (0.49-51) 0.20 
   0.881≤1.0 1.0 - 1.0 - 
Global p-value  0.012  0.0010 
P-value for trend  
 
 0.046  0.015 
Age (years) 
 
1.1 (1.0-1.1) <0.0010 1.1 (1.0-1.2) 0.010 
Sex      
   Male - - 1.0  
   Female  
 
- - 0.080  (0.0090- 0.71) 0.023 
Mutation severity     
    Not Severe - - 1.0  
    Severe  - - 5.2 (0.82-33) 0.080 
 
*5 missing values for mutation severity were included in a “missing category”  
 
 
 
